Castle Biosciences
CSTL
144 hedge funds and large institutions have $692M invested in Castle Biosciences in 2020 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 63 increasing their positions, 36 reducing their positions, and 12 closing their positions.
150% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 12
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
75% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 36
56% more capital invested
Capital invested by funds: $443M → $692M (+$249M)
14% more funds holding
Funds holding: 126 → 144 (+18)
7.67% more ownership
Funds ownership: 60.68% → 68.35% (+7.7%)
99% less call options, than puts
Call options by funds: $5K | Put options by funds: $791K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
Redwood Investments
Boston,
Massachusetts
|
+$12.8M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$12.7M |
| 3 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
+$10.9M |
| 4 |
BlackRock
New York
|
+$7.9M |
| 5 |
Goldman Sachs
New York
|
+$5.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$11.7M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$5.65M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$5.56M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$3.77M |
| 5 |
RI
RTW Investments
New York
|
-$2.66M |
CSTL Hedge Fund Activity: Q3 2020 in Review
144 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q3 2020, worth a combined $692M — up 56% from $443M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new CSTL positions and 12 closed out — a net gain of 18 holders — while 63 added to existing stakes and 36 trimmed.
The largest buyer was Redwood Investments, adding an estimated $12.8M. The largest seller was Morgan Stanley, cutting an estimated $11.7M.
- 144 institutional investors held Castle Biosciences (CSTL) as of Q3 2020, up from 126 in Q2 2020.
- Funds reported $692M of Castle Biosciences stock for Q3 2020, up 56% quarter-over-quarter.
- 30 funds opened new Castle Biosciences positions in Q3 2020 and 12 closed out, a net change of +18 holders.
- The largest Castle Biosciences buyer in Q3 2020 was Redwood Investments, an estimated $12.8M added.
- The largest Castle Biosciences seller in Q3 2020 was Morgan Stanley, an estimated $11.7M sold.
Based on aggregated 13F filings for Q3 2020.